Findings from a “real-world” study show that the multimodal minimally invasive glaucoma surgery (MIGS) device (Hydrus Microstent, Ivantis) safely and effectively treats a wide variety of glaucoma types, providing reductions in IOP and medication burden that are durable through at least three years.
Jeffrey Whitman, MD, reported the findings as the ASCRS-ASOA annual meeting, held May 3-7 at the Convention Center in San Diego, CA.
Dr. Whitman presented data from the SPECTRUM registry that was developed to collect outcomes data for patients treated with the MIGS device either in combination with cataract surgery or as a standalone procedure.
“It is important to state what is meant by ‘real-world’. The SPECTRUM registry includes all-comers,” said Dr. Whitman, president and chief surgeon, Key-Whitman Eye Center, Dallas, TX.
“It is a global, multicenter registry including data from 51 centers in 17 countries, all outside of the United States.”
Dr. Whitman noted that about 2,500 eyes were enrolled through 2018, and they were implanted with the MIGS device either in a combination procedure with phacoemulsification and IOL implantation or they were phakic or pseudophakic and had standalone glaucoma surgery.
“The large population of enrolled eyes also represents the full spectrum of glaucoma severity, from mild through advanced, including eyes with glaucoma refractory to prior incisional/filtration surgery,” he added.
Dr. Whitman has no relevant financial interests to disclose.